At a glance
ClinicalIndex Comparison RecordN/ACompleted· 12 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
12 articles- Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint InhibitorsGlobeNewswire Biotech·2026-06-30press release
- Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe diseaseEndpoints News·2026-06-30
- Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone diseaseEndpoints News·2026-06-29
- Edgewise to advance heart drug into Phase 3 following mid-stage data updateEndpoints News·2026-06-16
- Takeda fortifies orexin potential with more Phase 3 dataEndpoints News·2026-06-15
- Gan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma dataEndpoints News·2026-06-15
- Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3BioSpace·2026-06-15
- Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staffEndpoints News·2026-06-15
- <a href="https://www.fiercebiotech.com/biotech/edgewise-data-power-rival-bms-and-cytokinetics-toward-phase-3-despite-investor-doubts" hreflang="en">Edgewise data power rival to BMS and Cytokinetics toward phase 3</a>FierceBiotech
- <a href="https://www.fiercebiotech.com/biotech/soligenix-axes-lymphoma-program-after-phase-3-setback-mulls-ma-options" hreflang="en">Soligenix axes lymphoma program after phase 3 setback, mulls M&A options</a>FierceBiotech
- <a href="https://www.fiercebiotech.com/biotech/intellia-shares-paradigm-shifting-ph-3-data-one-time-treatment-hae-patients" hreflang="en">Intellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment</a>FierceBiotech
- <a href="https://www.fiercebiotech.com/biotech/astrazeneca-unveils-phase-3-bone-disease-data-behind-5b-forecast-strensiq-successor" hreflang="en">AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor</a>FierceBiotech
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
Assessment of Levels of Intracellular Cytokines and Markers in Cells Recovered From the Anterior Eye (Phase 3)
In Brief
An observational study for Impression Cytology. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This is a single arm, prospective, bilateral, non-randomized study that will be split into four elements. Element 1 will be an in vitro non-clinical study and described in the laboratory protocol. Elements 2, 3 and 4 will each be a single non-dispensing visit.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsImpression Cytology
CountriesUnited Kingdom
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartMar 2019
First PostedMar 2019
Primary CompletionSep 2019
TodayJul 2026
First PostedMar 29, 2019
Enrollment StartMar 28, 2019
Primary CompletionSep 15, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.3 years ago